A majority owned subsidiary of Vascular BioSciences, VBS Pharmaceuticals develops disease selective therapies for serious diseases. Our lead therapeutic candidate, CARSKNKDC (CAR) peptide, represents a new paradigm in targeted therapy. CAR preferentially homes to, and penetrates, diseased tissue while selectively augmenting the efficacy of co-administered therapies. In preclinical models, CAR can selectively enhance pulmonary hypertension therapies, boost sepsis survival, improve drug effectiveness, and reduce systemic side effects by enhancing the targeted delivery of therapeutics.
- Learn more about VBS Pharmaceuticals »
- Learn how CAR works »
- View current CAR disease applications »
A division of Vascular BioSciences, VBS Interventional develops and manufactures the world’s first endoarterial biopsy catheter, designed to uniquely access vital cellular information from the vasculature which will allow physicians to decipher and treat each patient according to their underlying vascular disease process.
- Learn more about VBS Interventional »
- Learn more about the endoarterial biopsy catheter »
- View current endoarterial biopsy catheter disease applications »
A division of Vascular BioSciences, VBS Molecular Diagnostics produces comprehensive profiles of vascular disease through the molecular analysis of endoarterial biopsy samples. Vascular profiling will allow faster and more definitive diagnosis, better matching of treatment to disease, personalized, targeted therapies, and the anticipation and avoidance of adverse health events.